• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human.

作者信息

Muraki Isao

机构信息

Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University.

出版信息

J Atheroscler Thromb. 2021 Apr 1;28(4):317-318. doi: 10.5551/jat.ED144. Epub 2020 Oct 1.

DOI:10.5551/jat.ED144
PMID:32999210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8147015/
Abstract
摘要

相似文献

1
Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）在人体脂质代谢和胰岛素抵抗中的作用。
J Atheroscler Thromb. 2021 Apr 1;28(4):317-318. doi: 10.5551/jat.ED144. Epub 2020 Oct 1.
2
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂治疗常染色体隐性高胆固醇血症——简要报告
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1647-50. doi: 10.1161/ATVBAHA.116.307493. Epub 2016 Apr 14.
3
Role of PCSK9 in lipid metabolism and atherosclerosis.PCSK9 在脂代谢和动脉粥样硬化中的作用。
Biomed Pharmacother. 2018 Aug;104:36-44. doi: 10.1016/j.biopha.2018.05.024. Epub 2018 May 11.
4
Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.在高剂量他汀类药物治疗的高胆固醇血症患者中，静脉注射阻断前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 的人源化单克隆抗体 Bocizumab 治疗 12 周的效果。
Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12308. Epub 2017 Nov 25.
5
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.不同降脂策略后低密度脂蛋白胆固醇、游离前蛋白转化酶枯草溶菌素/克新9型与阿利西尤单抗水平之间的关系
J Am Heart Assoc. 2016 Jun 10;5(6):e003323. doi: 10.1161/JAHA.116.003323.
6
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.在接受和不接受阿托伐他汀治疗的高胆固醇血症患者中单次和多次给予 bococizumab（一种人源化 IgG2Δa 单克隆抗体，与前蛋白转化酶枯草溶菌素/糜蛋白酶 9 结合）的效果：四项 I 期研究的结果。
Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12309. Epub 2017 Nov 23.
7
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.前蛋白转化酶枯草溶菌素9的生物学特性：超越降低低密度脂蛋白胆固醇
Cardiovasc Res. 2016 Oct;112(1):429-42. doi: 10.1093/cvr/cvw194. Epub 2016 Aug 5.
8
[PCSK9 inhibitors : New treatment option in clinical practice].[前蛋白转化酶枯草溶菌素9抑制剂：临床实践中的新治疗选择]
Herz. 2016 Jun;41(4):290-5. doi: 10.1007/s00059-016-4434-4.
9
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.以 PCSK9 为靶点，降低低密度脂蛋白胆固醇：一种有前途的新机制。
Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29.
10
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.前蛋白转化酶枯草溶菌素 9 丝氨酸蛋白酶抑制剂对原发性高胆固醇血症患者血脂水平和结局的影响：网状荟萃分析。
Eur Heart J. 2016 Feb 7;37(6):536-45. doi: 10.1093/eurheartj/ehv563. Epub 2015 Nov 17.

引用本文的文献

1
Regulatory mechanisms of hepatocyte PCSK9 expression: translating mechanistic insights into potential nutraceuticals.肝细胞中前蛋白转化酶枯草溶菌素9（PCSK9）表达的调控机制：将机制性见解转化为潜在的营养保健品
Chin Med. 2025 Aug 5;20(1):121. doi: 10.1186/s13020-025-01178-y.
2
Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis.PCSK9抑制剂在心血管高危患者中的应用价值：一项荟萃分析
Iran J Public Health. 2023 May;52(5):903-912. doi: 10.18502/ijph.v52i5.12707.

本文引用的文献

1
Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.在一般人群中，血清前蛋白转化酶枯草溶菌素 9（PCSK9）与胰岛素抵抗、甘油三酯、脂蛋白（a）水平独立相关，但与低密度脂蛋白胆固醇水平无关。
J Atheroscler Thromb. 2021 Apr 1;28(4):329-337. doi: 10.5551/jat.56390. Epub 2020 Jul 4.
2
Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis.24 小时活动周期是否影响血浆 PCSK9 浓度？系统评价和荟萃分析。
Curr Atheroscler Rep. 2020 Jun 16;22(7):30. doi: 10.1007/s11883-020-00843-x.
3
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.《心脏病与卒中统计-2020 更新：来自美国心脏协会的报告》。
Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29.
4
Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.循环 PCSK9 与肝生物标志物和肝脂肪变性有关。
Clin Biochem. 2020 Mar;77:20-25. doi: 10.1016/j.clinbiochem.2020.01.003. Epub 2020 Jan 20.
5
Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils Lowers Atherogenic Lipoprotein Classes Without Increasing Lipoprotein(a).用核桃或植物油中的不饱和脂肪代替饱和脂肪可降低致动脉粥样硬化脂蛋白的种类，而不会增加脂蛋白(a)。
J Nutr. 2020 Apr 1;150(4):818-825. doi: 10.1093/jn/nxz313.
6
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.日本动脉粥样硬化协会（JAS）2017年动脉粥样硬化性心血管疾病预防指南。
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984. doi: 10.5551/jat.GL2017. Epub 2018 Aug 22.
7
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.循环型前蛋白转化酶枯草溶菌素 9（PCSK9）可独立于既定危险因素预测未来心血管事件的风险。
Circulation. 2016 Mar 29;133(13):1230-9. doi: 10.1161/CIRCULATIONAHA.115.018531. Epub 2016 Feb 19.
8
Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study.利用日本城市人群的危险因素类别预测冠心病，并与弗雷明汉风险评分进行比较：吹田研究
J Atheroscler Thromb. 2014;21(8):784-98. doi: 10.5551/jat.19356. Epub 2014 Mar 25.
9
Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment.甲基化砷化合物：啮齿动物代谢和致癌性研究对人类风险评估的启示
Crit Rev Toxicol. 2006 Feb;36(2):99-133. doi: 10.1080/10408440500534230.
10
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.前蛋白转化酶枯草溶菌素9（PCSK9）基因的突变会导致常染色体显性遗传高胆固醇血症。
Nat Genet. 2003 Jun;34(2):154-6. doi: 10.1038/ng1161.